Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanne Vestergaard

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Danish Medical Journal|March 23, 2022
A retrospective cohort study of patients with eosinophilia referred to a tertiary centreMette Hougaard, Gundhild Nynke Thomsen, Thomas Kielsgaard Kristensen, et al.
Haematologica|July 2, 2011
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalitiesLars Möllgård, Leonie Saft, Marianne Bach Treppendahl, et al.
British Journal of Haematology|June 14, 2013
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemiaChristen L Andersen, Mary F McMullin, Elisabeth Ejerblad, et al.
BMJ Open|April 27, 2026
Redispensing oral anticancer drugs in Denmark (DANROAD): a national, multicentre, prospective implementation study protocolAnne Suhr Thykjær Petersen, Kathrine Bendorff Moriat, Charlotte Bekker, et al.
Frontiers in Oncology|June 5, 2023
The multidisciplinary approach to eosinophiliaGunhild Nynke Thomsen, Mette Niemann Christoffersen, Hanne Merete Lindegaard, et al.
Leukemia|July 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI TrialFabio Efficace, Francois-Xavier Mahon, Johan Richter, et al.
Acta Dermato-Venereologica|December 24, 2015
Multidisciplinary Management of Mastocytosis: Nordic Expert Group ConsensusSigurd Broesby-Olsen, Ingunn Dybedal, Theo Gülen, et al.
Leukemia Research|May 20, 2014
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostatChristen Lykkegaard Andersen, Mads Emil Bjørn, Mary Frances McMullin, et al.
The Lancet. Oncology|May 9, 2018
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trialSusanne Saussele, Johan Richter, Joelle Guilhot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free RemissionFrancois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Danish Medical Journal|March 23, 2022
A retrospective cohort study of patients with eosinophilia referred to a tertiary centreMette Hougaard, Gundhild Nynke Thomsen, Thomas Kielsgaard Kristensen, et al.
Haematologica|July 2, 2011
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalitiesLars Möllgård, Leonie Saft, Marianne Bach Treppendahl, et al.
British Journal of Haematology|June 14, 2013
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemiaChristen L Andersen, Mary F McMullin, Elisabeth Ejerblad, et al.
BMJ Open|April 27, 2026
Redispensing oral anticancer drugs in Denmark (DANROAD): a national, multicentre, prospective implementation study protocolAnne Suhr Thykjær Petersen, Kathrine Bendorff Moriat, Charlotte Bekker, et al.
Frontiers in Oncology|June 5, 2023
The multidisciplinary approach to eosinophiliaGunhild Nynke Thomsen, Mette Niemann Christoffersen, Hanne Merete Lindegaard, et al.
Leukemia|July 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI TrialFabio Efficace, Francois-Xavier Mahon, Johan Richter, et al.
Acta Dermato-Venereologica|December 24, 2015
Multidisciplinary Management of Mastocytosis: Nordic Expert Group ConsensusSigurd Broesby-Olsen, Ingunn Dybedal, Theo Gülen, et al.
Leukemia Research|May 20, 2014
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostatChristen Lykkegaard Andersen, Mads Emil Bjørn, Mary Frances McMullin, et al.
The Lancet. Oncology|May 9, 2018
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trialSusanne Saussele, Johan Richter, Joelle Guilhot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free RemissionFrancois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.
Pageof 7